The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab

G309 or S310 mutations on the HER2 extracellular domain II induce receptor activation. Clinically, S310F is most frequent among HER2 extracellular domain mutations and patients with the S310F mutation without HER2 amplification responded to trastuzumab with or without the pertuzumab combination. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Jung Won, Kim, Soohyun, Ha, Suji, Choi, Byungsan, Kim, Seongyeong, Im, Seock-Ah, Yoon, Tae-Young, Chung, Junho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843359/
https://www.ncbi.nlm.nih.gov/pubmed/31635022
http://dx.doi.org/10.3390/biom9100629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843359/
https://www.ncbi.nlm.nih.gov/pubmed/31635022
http://dx.doi.org/10.3390/biom9100629

Ejemplares similares